Aspirin in primary prevention of cardiovascular disease in diabetes
It is well established that people with diabetes are at an increased risk of cardiovascular disease compared with those without diabetes. Although the protective role of aspirin in secondary prevention is well documented, its role in primary prevention of cardiovascular disease in people with diabet...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487832/ https://www.ncbi.nlm.nih.gov/pubmed/36161214 http://dx.doi.org/10.5114/amsad.2021.105596 |
_version_ | 1784792527879012352 |
---|---|
author | Papazafiropoulou, Athanasia K. Melidonis, Andreas Antonopoulos, Stavros |
author_facet | Papazafiropoulou, Athanasia K. Melidonis, Andreas Antonopoulos, Stavros |
author_sort | Papazafiropoulou, Athanasia K. |
collection | PubMed |
description | It is well established that people with diabetes are at an increased risk of cardiovascular disease compared with those without diabetes. Although the protective role of aspirin in secondary prevention is well documented, its role in primary prevention of cardiovascular disease in people with diabetes, after the results of major clinical trials and meta-analyses, is unclear. The observed discrepancies might be explained in part in terms of the differences between the background cardiovascular risks, follow-up periods, age and gender of the study populations. Recently, the results of the ASCEND trial in people with diabetes documented the cardiovascular benefit of aspirin for primary prevention, but with an increased risk of bleeding that might outweigh the observed cardiovascular benefit. Therefore, current guidelines recommend its use for primary prevention in people with and without diabetes under specific circumstances. The purpose of the present review is to summarize the existing literature data regarding the place that aspirin has in primary prevention of cardiovascular disease in people with diabetes. |
format | Online Article Text |
id | pubmed-9487832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-94878322022-09-22 Aspirin in primary prevention of cardiovascular disease in diabetes Papazafiropoulou, Athanasia K. Melidonis, Andreas Antonopoulos, Stavros Arch Med Sci Atheroscler Dis State of the Art Paper It is well established that people with diabetes are at an increased risk of cardiovascular disease compared with those without diabetes. Although the protective role of aspirin in secondary prevention is well documented, its role in primary prevention of cardiovascular disease in people with diabetes, after the results of major clinical trials and meta-analyses, is unclear. The observed discrepancies might be explained in part in terms of the differences between the background cardiovascular risks, follow-up periods, age and gender of the study populations. Recently, the results of the ASCEND trial in people with diabetes documented the cardiovascular benefit of aspirin for primary prevention, but with an increased risk of bleeding that might outweigh the observed cardiovascular benefit. Therefore, current guidelines recommend its use for primary prevention in people with and without diabetes under specific circumstances. The purpose of the present review is to summarize the existing literature data regarding the place that aspirin has in primary prevention of cardiovascular disease in people with diabetes. Termedia Publishing House 2021-04-22 /pmc/articles/PMC9487832/ /pubmed/36161214 http://dx.doi.org/10.5114/amsad.2021.105596 Text en Copyright: © 2021 Termedia & Banach https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | State of the Art Paper Papazafiropoulou, Athanasia K. Melidonis, Andreas Antonopoulos, Stavros Aspirin in primary prevention of cardiovascular disease in diabetes |
title | Aspirin in primary prevention of cardiovascular disease in diabetes |
title_full | Aspirin in primary prevention of cardiovascular disease in diabetes |
title_fullStr | Aspirin in primary prevention of cardiovascular disease in diabetes |
title_full_unstemmed | Aspirin in primary prevention of cardiovascular disease in diabetes |
title_short | Aspirin in primary prevention of cardiovascular disease in diabetes |
title_sort | aspirin in primary prevention of cardiovascular disease in diabetes |
topic | State of the Art Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487832/ https://www.ncbi.nlm.nih.gov/pubmed/36161214 http://dx.doi.org/10.5114/amsad.2021.105596 |
work_keys_str_mv | AT papazafiropoulouathanasiak aspirininprimarypreventionofcardiovasculardiseaseindiabetes AT melidonisandreas aspirininprimarypreventionofcardiovasculardiseaseindiabetes AT antonopoulosstavros aspirininprimarypreventionofcardiovasculardiseaseindiabetes |